Skip to main content
25 January 2021
Last updated:
Monday 25 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Clinical Research

Targovax reports promising oncolytic virus data

Wednesday 2 December 2020
Country

Norway

Norway-based Targovax ASA has reported promising Phase 1 data for its oncolytic virus treatment ONCOS-102 in combination with pembrolizumab in patients with advanced, unresectable melanoma. The patients had experienced disease progression despite treatment with a checkpoint inhibitor, yet in the study tumour responses were observed in seven out of 20 evaluable patients.

Read more

Galapagos reports data for IPF treatment

Tuesday 1 December 2020
Country

Belgium

Galapagos NV has reported positive topline data from an early clinical trial of a small molecule antagonist of GPR84 in patients with idiopathic pulmonary fibrosis. The placebo-controlled study enrolled 68 patients but was not powered to show statistical significance. Nevertheless, patients receiving the treatment GLPG1205 on top of a standard of care showed a smaller decline in forced vital capacity, a measure of lung function, than those receiving a placebo and standard of care.

Read more

Moderna makes Covid-19 regulatory filings

Monday 30 November 2020
Country

United States

Moderna Inc is poised to make regulatory filings in the US and Europe today for its Covid-19 vaccines. This follows the release of new data from a Phase 3 study showing that the messenger RNA (mRNA) vaccine achieved an efficacy rate of 94.1%. The placebo-controlled study involves 30,000 participants.

Read more

AZ to further evaluate Covid-19 vaccine dose

Friday 27 November 2020
Country

United Kingdom

AstraZeneca Plc is to further evaluate the dosing for its candidate Covid-19 vaccine AZD1222 in light of interim data from trials in the UK and Brazil showing different efficacy rates for different dosing regimens. The data were disclosed on 23 November and showed vaccine efficacy of 90% when given as a half dose followed by a full dose at least one month apart. An efficacy rate of 62% was achieved when given as two full doses at least one month apart.

Read more

Genmab stops development of ADC

Thursday 26 November 2020
Country

Denmark

Genmab A/S has stopped development of enapotamab vedotin, an antibody-drug conjugate being investigated for the treatment of solid tumours after early clinical data did not meet the company’s criteria. “While enapotamab vedotin has shown some evidence of clinical activity, this was not optimised by different dose schedules and/or predictive biomarkers,” the company said on 24 November.

Read more

AZ and Oxford report vaccine efficacy

Monday 23 November 2020
Country

United Kingdom

AstraZeneca Plc and the University of Oxford have become the third developers to report high levels of efficacy for their experimental vaccine to prevent Covid-19. The partners are now preparing for regulatory submissions, and have reaffirmed a commitment to supply their vaccine globally on a not-for-profit basis for the duration of the pandemic.

Read more

Novartis gets rights to allogeneic cell therapy

Saturday 21 November 2020
Country

Switzerland

Novartis has entered into a licencing and collaboration agreement with Australia-based Mesoblast Ltd to further develop and commercialise remestemcel-L, an allogeneic cell therapy for the treatment of a number of inflammatory disorders. These include acute respiratory distress syndrome, and that associated with Covid-19. Acute respiratory distress syndrome is a type of respiratory failure characterised by the rapid onset of inflammation in the lungs.

Read more

BioNTech/Pfizer vaccine shows final efficacy of 95%

Wednesday 18 November 2020
Country

Germany

BioNTech SE of Germany and its partner Pfizer Inc, announced final Phase 3 data for their Covid-19 vaccine on 18 November which showed a vaccine efficacy rate of 95%. The vaccine BNT162b2 is based on messenger RNA (mRNA) technology. The study met all of its primary efficacy endpoints. The efficacy rate applies to participants without prior SARS-CoV-2 infection, the first primary objective, and also to participants with and without prior SARS-CoV-2 infection, the second primary objective.

Read more

Moderna vaccine shows 94.5% efficacy

Tuesday 17 November 2020
Country

United States

Moderna Inc said that its candidate vaccine, mRNA-1273, was 94.5% effective in preventing Covid-19 disease in a large Phase 3 study that enrolled more than 30,000 participates in the US. The compound is a messenger RNA (mRNA) vaccine against Covid-19 encoding for a prefusion stabilised form of the SARS-CoV-2 spike protein. It was co-developed by Moderna and the US National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.

Read more

Positive data for candidate heart treatment

Monday 16 November 2020
Country

Germany

Germany-based Cardior Pharmaceuticals GmbH has announced positive results from a Phase 1b study of its lead compound CDR132L, an antisense oligonucleotide, for heart failure. The study was performed in cooperation with Richmond Pharmacology Ltd in London, UK and the results were published in the European Heart Journal on 12 November 2020. In the trial, CDR132L met all the endpoints including safety and tolerability.

Read more

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to Clinical Research

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

T-knife appoints Thomas Soloway as chief executive
Thursday January 21 2021
Domainex makes two executive appointments
Thursday January 21 2021
Richard Francis named CEO of Purespring
Tuesday January 19 2021
Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.